1.415USD+0.35%Mkt Cap: 174.92M USDP/E: —Last update: 2026-05-26
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a pr…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap174.92M USD
Enterprise Value-19.35M USD
Revenue (TTM)1.55M USD
Gross Profit1.55M USD
Net Income (TTM)-63.06M USD
Revenue/Share0.0180 USD
Last Price1.415 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees38
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.45
PEG—
EV/EBITDA0.31
EV/Revenue-12.52
P/S122.40
P/B4.46
EPS (TTM)-0.64
EPS (Forward)-1.04
52W Range
1.00020% of range3.060
52W High3.060 USD
52W Low1.000 USD
Profitability
Gross Margin100.00%
Oper. Margin-1116.23%
EBITDA Margin0.00%
Profit Margin-4078.78%
ROE-150.97%
ROA-55.53%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-49.04M USD
CapEx (TTM)302.00K USD
FCF Margin-1869.55%
FCF Yield-16.52%
Net Debt-47.58M USD
Net Debt/EBITDA0.77
Balance Sheet
Debt/Equity1.40
Current Ratio8.01
Quick Ratio7.83
Book Value/Sh0.3410 USD
Cash/Share6.456 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)6.333 USD
Target Range2.000 USD – 8.000 USD
# Analysts6
Ownership
Shares Out.124.50M
Float14.07M
Insiders2.48%
Institutions24.99%
Short Interest
Short Ratio3.1d
Short % Float6.58%
Short % Out.6.53%
Shares Short7.81M
Short (prev mo.)8.45M
Technical
SMA 501.697 (-16.6%)
SMA 2001.898 (-25.5%)
Beta1.04
S&P 52W Chg28.31%
Avg Vol (30d)1.57M
Avg Vol (10d)1.88M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—